Mallinckrodt plc
Case Number:
1:20-bk-12522
Court:
Nature of Suit:
Firms
- Abernathy Roeder
- Abrams & Bayliss
- Akin Gump
- Andrews & Thornton
- ArentFox Schiff
- Arnold & Porter
- Ashby & Geddes
- ASK LLP
- Bailey & Glasser
- Barrack Rodos
- Bartimus Frickleton
- Beasley Firm
- Benesch
- Berger Harris
- Bielli & Klauder
- Bilzin Sumberg
- Binder & Schwartz
- Blank Rome
- Bragar Eagel
- Brown & Connery
- Brown Rudnick
- Buchalter APC
- Campbell & Levine
- Caplin & Drysdale
- Carlton Fields
- Carothers & Hauswirth
- Chamberlain Hrdlicka
- Chiesa Shahinian
- Chipman Brown
- Ciardi Ciardi
- Clark Hill
- Cole Schotz
- Connolly Gallagher
- Consovoy McCarthy
- Cooch & Taylor
- Cooley LLP
- Covington & Burling
- Cozen O'Connor
- Cross & Simon
- Crowell & Moring
- David Christian Attorneys LLC
- Dechert LLP
- Dentons
- DLA Piper
- Doroshow Pasquale
- Dorsey & Semrau
- Duane Morris
- Eimer Stahl
- Eiseman Levine
- Elliott Greenleaf
- Faegre Drinker
- Finson Law Firm
- Fishman Haygood
- Flaster Greenberg
- Foley & Lardner
- Fox Rothschild
- Fox Swibel
- FrankelWyron
- FrankGecker
- Frazer PLC
- Friedman Kaplan
- Gellert Scali
- Gibson Dunn
- Gilbert LLP
- Goldstein & McClintock
- Goodwin Procter
- GrayRobinson
- Greenberg Traurig
- Hackett Feinberg
- Hagens Berman
- Halperin Battaglia
- Haviland Hughes
- Henrichsen Law Group
- Herrick Feinstein
- Hobbs Straus
- Hogan McDaniel
- Hughes Socol
- Hunton Andrews
- Jenner & Block
- Jones Day
- Katten Muchin
- Kay Casto
- Keller Postman
- Kennedys Law LLP
- Klehr Harrison
- Kleinberg Kaplan
- K&L Gates
- Kobre & Kim
- Kramer Levin
- Landis Rath
- Latham & Watkins
- Lathrop GPM
- Law Office of Curtis A. Hehn
- Leader Berkon
- Leech Tishman
- Levenfeld Pearlstein
- Lewis Brisbois
- Linebarger Goggan
- Lippes Mathias
- Locke Lord
- Loeb & Loeb
- Lowenstein Sandler
- Lowey Dannenberg
- MacElree Harvey
- Margolis Edelstein
- Martzell Bickford
- Maschoff Brennan
- McCarter & English
- McDermott Will & Emery
- McGivney Kluger
- McLaughlin Law Office
- Mehri & Skalet
- Meyers & Flowers
- Michael Best & Friedrich LLP
- Miller & Martin
- Miller Nash LLP
- Montgomery McCracken
- Monzack Mersky
- Morgan Lewis
- Morris James
- Morris Nichols
- Moses & Singer
- Motley Rice
- Munsch Hardt
- Napoli Shkolnik
- Norton Rose
- Obermayer Rebmann
- Ogletree Deakins
- O'Melveny & Myers
- Pachulski Stang
- Parkowski Guerke
- Paul Hastings
- Paul Weiss
- Perdue Brandon
- Phillips Lytle
- Potter Anderson
- Powell Firm
- Pryor Cashman
- Quinn Emanuel
- Reed Smith
- Richards Layton
- Robbins Geller
- Robbins Russell
- Robinson & Cole
- Rolnick Kramer
- Rosner Law Group LLC
- Ross Aronstam
- Ross Smith & Binford
- Saul Ewing
- Schulte Roth
- Sequor Law
- Seward & Kissel
- Sherrard Roe
- Shipman & Goodwin
- Simon Greenstone
- Singer & Levick
- Sirlin Lesser
- Skadden Arps
- Skikos Crawford
- Smith Katzenstein
- Sonosky Chambers
- Stevens & Lee
- Stradley Ronon
- Stutzman Bromberg
- Sullivan & Cromwell
- Sullivan Hazeltine
- Sussman Shank
- Taft Stettinius
- The Cooper Law Firm
- Togut Segal
- Troutman Pepper
- Wachtell Lipton
- Warner Norcross
- White & Case
- Whiteford Taylor
- Willkie Farr
- WilmerHale
- Wilson Sonsini
- Womble Bond
- Young Conaway
Companies
- Aetna Inc.
- AlixPartners LLP
- Allianz Global Investors GmbH
- American Federation of State County & Municipal Employees
- Anda Inc.
- ASM Capital LP
- Berkshire Hathaway Inc.
- Bristol-Myers Squibb Co.
- Callidus Software Inc.
- Cardinal Health Inc.
- Catalent Inc.
- Cencora Inc.
- Cephalon Inc.
- CNA Financial Corp.
- Concur Technologies, Inc.
- Conduent Inc.
- Constellation Energy Corp.
- Cornerstone Research Inc.
- Covance Inc.
- Covidien PLC
- CSX Corp.
- CVS Health Corp.
- Deloitte Touche Tohmatsu Ltd.
- Deutsche Bank AG
- Ducera Partners LLC
- Duke Energy Corp.
- Endo International PLC
- Ernst & Young LLP
- Express Scripts Holding Co.
- Ferguson Enterprises Inc.
- Fresenius Kabi AG
- Guggenheim Partners LLC
- HealthCor Partners Management LP
- Henry Schein Inc.
- Humana Inc.
- Integrated Benefits Inc.
- Iqvia Holdings Inc.
- Iron Mountain Inc.
- Ironshore Inc.
- Jefferies Financial Group Inc.
- Johnson Controls International PLC
- Johnson & Johnson
- JPMorgan Chase & Co.
- Liberty Mutual Insurance Group
- LifeWallet
- Lumen Technologies Inc.
- McKesson Corp.
- Medco Health Solutions Inc.
- Microsoft Corp.
- Morgan Stanley
- New York State Electric & Gas Corp.
- Old Dominion Freight Line Inc.
- Olin Corp.
- Optum Inc.
- OptumRx Inc.
- Oracle Corp.
- Paulson & Co. Inc.
- PCI Pharma Services
- Perrigo Co. PLC
- Province LLC
- Quantitative Investment Management LLC
- Rain for Rent Inc.
- SAP AG
- Southeastern Freight Lines Inc.
- State Teachers Retirement System of Ohio
- Stretto Inc.
- Teva Pharmaceutical Industries Ltd.
- The Goldman Sachs Group Inc.
- Third Point LLC
- United Association
- United BioSource Corp.
- University of Iowa
- University of Toledo
- U.S. Bancorp
- Wells Fargo & Co.
Government Agencies
- City of Syracuse, New York
- Minnesota Department of Revenue
- Mississippi Division of Medicaid
- Missouri Department of Revenue
- Ohio Department of Taxation
- State of Indiana
- State of Michigan
- Texas Comptroller of Public Accounts
- Texas Workforce Commission
Sectors & Industries:
-
November 18, 2021
Mallinckrodt Ch. 11 Plan Hearing Won't Restart Monday
The Delaware bankruptcy judge overseeing Mallinckrodt's Chapter 11 case Thursday granted requests to delay the resumption of the drugmaker's plan confirmation hearing, saying he first needs to digest claims it engaged in drug price manipulation.
-
November 17, 2021
Mallinckrodt Denies Manipulating Acthar Market
Mallinckrodt closed its defense against claims it inflated the price of its Acthar gel on Wednesday, with witnesses saying that the drugmaker didn't suppress a competing product and that the speaking fees it paid to doctors didn't increase sales.
-
November 16, 2021
Mallinckrodt Says Insurers' Acthar Claims Off By $317M
An expert witness for Mallinckrodt told a Delaware bankruptcy judge Tuesday that two insurers seeking more than $317 million in damages wouldn't be owed any more than $2.6 million even if their claims that the drugmaker suppressed competition for its Acthar gel were true.
-
November 15, 2021
Mallinckrodt Exec Says Acthar Price Hikes Were Necessary
A Mallinckrodt executive defended the pricing and marketing of the drugmaker's Acthar gel on Monday as a pair of insurers presented a Delaware judge with the last of their evidence that Mallinckrodt engaged in a yearslong scheme to drive up Acthar's cost.
-
November 12, 2021
Insurers Say Mallinckrodt Sales Strategy Cost Them $320M
A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid more than $320 million for Acthar over the past year.
-
November 08, 2021
Insurers Claim Mallinckrodt Inflated Acthar Price By $300M
A pair of health insurers told a Delaware bankruptcy judge Monday that Mallinckrodt PLC owes them more than $300 million because of the drugmaker's alleged efforts to keep a cheaper alternative to its Acthar infantile spasm drug off the market.
-
November 05, 2021
Mallinckrodt Cleared On $94M Ch. 11 Bond Penalty
A Delaware bankruptcy judge on Friday found Mallinckrodt does not owe a $94 million payment to noteholders, saying the creditors should not get a "windfall" simply as a result of the drugmaker's Chapter 11 filing.
-
November 04, 2021
Mallinckrodt Can Duck Acthar Royalties In Chapter 11
A bankruptcy judge in Delaware Thursday ruled drugmaker Mallinckrodt can use Chapter 11 to escape royalty payments for the sale of its Acthar Gel medication as the confirmation hearing for the company's restructuring plan continued.
-
November 02, 2021
Antitrust Group Says Mallinckrodt Plan Lacks Sufficient Votes
A group with antitrust claims against drugmaker Mallinckrodt challenged the vote approving the company's Chapter 11 plan on Tuesday, but lost a bid to get counsel for the unsecured creditors on the stand to address the vote solicitation process.
-
October 15, 2021
Mallinckrodt Ch.11 Plan Under Fire From Multiple Angles
The drugmaker Mallinckrodt is facing more than a dozen objections to its proposed reorganization plan as it heads for a confirmation hearing in a Delaware bankruptcy court in just over two weeks, on grounds ranging from liability releases to insurance claims to bond terms.